REM 422
Alternative Names: REM-422Latest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator Remix Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-myb expression inhibitors; RNA degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia; Adenoid cystic carcinoma; Myelodysplastic syndromes
Most Recent Events
- 20 Nov 2024 Pharmacodynamics data from a preclinical trial in Acute Myeloid Leukemia released by Remix Therapeutics
- 23 Oct 2024 Pharmacodynamics data from preclinical studies in Adenoid cystic carcinoma presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2024)
- 13 Jun 2024 Pharmacodynamics data from a preclinical studies in Acute myeloid leukemia presented at the 29th Congress of the European Haematology Association (EHA-2024)